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demonstrated a response similar to non-diabetic mice when 
tested with an intraperitoneal glucose tolerance test. Cham-
ber tissue from this group contained islets with insulin-pro-
ducing   cells adjacent to the vascular pedicle. Islets seeded 
onto Gelitaspon with NGF and sited on femoral vessels using 
a tissue-engineering chamber offer an alternative method 
for islet transplantation in diabetic mice. This may have po-
tential as a method for clinical islet transplantation. 
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 Abstract 
 Intraportal islet transplantation has shown initial promise for 
the treatment of type 1 diabetes. However, the portal vein 
site is associated with complications such as thrombosis and 
hepatic steatosis, leading to transplant failure. The aims of 
this study were to (1) test the feasibility of an alternative islet 
transplantation method that utilises a FDA-approved gelatin 
sponge as a novel islet carrier and (2) assess if exogenous ad-
dition of nerve growth factor (NGF) has any additional ben-
eficial effects on graft performance in diabetic mice. Mice 
were rendered diabetic by a single intraperitoneal injection 
of streptozotocin. Five hundred syngeneic islets were seed-
ed onto a Gelitaspon  disc in the presence or absence of 
NGF, and placed into a silicone chamber surrounding the 
femoral neurovascular pedicle. Islet function was assessed 
by weekly monitoring of blood glucose levels and an intra-
peritoneal glucose tolerance test performed at the end of 
the study. Chambers were harvested for further histological 
analysis. Four of five mice transplanted with islets seeded 
onto Gelitaspon with NGF showed a significant reduction in 
blood glucose levels by 4 weeks after transplantation, and 
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Abbreviations used in this paper
APES 3-aminopropyltriethoxysilane
bFGF basic fibroblast growth factor
BG blood glucose
DAB diaminobenzaldehyde
HE haematoxylin and eosin
IPGTT intraperitoneal glucose tolerance test
NFBG non-fasting blood glucose
NGF nerve growth factor
NHMRC national health and medical research council
PBS phosphate buffered saline
STZ streptozotocin
T1D type 1 diabetes
TH hydroxylase
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 Introduction 
 Type 1 diabetes (T1D) is an autoimmune-mediated 
disorder that destroys the insulin-producing   cells of the 
pancreas [Wild et al., 2004]. At present, treatment for pa-
tients with T1D involves rigorous insulin supplementa-
tion and blood glucose (BG) monitoring. Although this 
treatment regimen does improve the condition, patients 
can still experience hypoglycaemic attacks, and it offers 
no guarantee that they will avoid secondary complica-
tions such as retinopathy, nephropathy, neuropathy and 
accelerated cardiovascular disease in later life [Shamoon 
et al., 1993; Genuth et al., 1999; Marzorati et al., 2007]. An 
improved glycaemic control can be restored in T1D pa-
tients with   cell replacement, thereby preventing or de-
laying the onset of associated secondary complications.
 The replacement of   cell mass may be achieved 
through whole pancreas transplantation or pancreatic 
islet transplantation. The former procedure is demand-
ing and patients require a lifelong immunosuppressant 
regimen. It is often associated with concomitant kidney 
transplantation, and is preferred in diabetic patients 
with end-stage renal failure [Robertson et al., 2000]. In 
2000, islet transplantation via intraportal infusion into 
the liver (the Edmonton Protocol) was thought to herald 
a new era of clinical islet transplantation [Shapiro et al., 
2000]. Short-term clinical studies initially reported a 1-
year insulin-independent rate of  1 80% [Froud et al., 
2005]. However, the long-term outcome has not been as 
promising as initial expectations [Shapiro et al., 2006]. 
After 5 years, 85% of the patients had well-controlled 
HbA1c levels, no episodic hypoglycemia and a signifi-
cant reduction in the daily insulin requirement. How-
ever, only 10% of the patients were free from exogenous 
insulin [Matas et al., 2005; Shapiro et al., 2006]. Today, 
clinical islet transplantation is restricted to patients with 
labile T1D. These patients experience rapid, out-of-pro-
portion BG changes despite intensive insulin manage-
ment and practice.
 The site for clinical islet transplantation is the portal 
vein of the liver. Immunologically, the liver has been con-
sidered an advantageous site requiring less immunosup-
pression as a solid organ transplant compared to other 
transplanted organs. This, and the early success of au-
tologous islet transplantation, made the liver the ideal site 
[Najarian et al., 1979; Bromberg et al., 2007]. However, 
portal hypertension, the risk of haemorrhage, portal vein 
thrombosis and gall bladder injury, although rare, are all 
significant complications [Ryan et al., 2004]. Altered liv-
er function and hepatic steatosis have also been reported 
[Ryan et al., 2004]. The hepatic transplantation site itself 
also carries a significant morbidity for islets. This site ex-
poses them to an environment containing toxins and im-
munosuppressive drugs [Balamurugan et al., 2006], and 
the microenvironment around the engrafted islets may 
be hypoxic and prone to local inflammation [Barshes et 
al., 2005]. Some reports also suggest that allogeneic cells 
dispersed in the portal vein can generate alloantibodies, 
some of which may be produced by the liver [Campbell et 
al., 2007]. Thus, the liver may not be the ideal site for islet 
transplantation.
 Experimental islet transplantation studies have inves-
tigated several alternative anatomical sites. These include 
the peritoneum, the epididymal fat pad, muscle, spleen, 
the mammary fat pad, the omentum and renal capsule 
[Balamurugan et al., 2006]. More recently, intravascular 
transplantation of encapsulated islets has been trialed as 
a possible treatment for T1D, with promising results [Pro-
chorov et al., 2008]. Our preliminary studies in this field 
have used a tissue-engineering chamber model based on 
the superficial epigastric pedicle using bFGF-supple-
mented Matrigel TM as the carrier matrix for the trans-
planted islets. Our initial results showed relatively poor 
vascularisation of tissue. As Matrigel is a basement mem-
brane extract derived from the Engelbreth-Holm-Swarm 
mouse sarcoma means this method has limited use. Geli-
taspon  , a biodegradable FDA-approved gelatin sponge 
has homology to human collagen and may provide a suit-
able vehicle for islet transplantation. Islet function and 
survival is dependent on a number of intrinsic factors. 
One factor is the neurotrophin nerve growth factor 
(NGF). NGF has been shown to play a regulatory role in 
  cell function [Polak et al., 1993], in particular in poten-
tiating insulin secretion [Frodin et al., 1995; Rosenbaum 
et al., 2001], and has been shown to improve   cell func-
tion and prolong survival of transplanted mouse islets in 
vitro and in vivo when used in a bolus dose [Miao et al., 
2005, 2006]. More recently, NGF has been shown to have 
pro-angiogenic and pro-arteriogenic properties [Emanu-
eli et al., 2002]. All of these studies have used NGF at 
various concentrations as a bolus dose ranging from 50 
to 500 ng/ml. However, a dose between 50 and 100 ng/ml 
can produce a biological response. Gelitaspon in combi-
nation with NGF may be a promising alternative method 
for human islet transplantation.
 The aims of this study were to (1) investigate the feasi-
bility of incorporating the femoral neurovascular bundle 
into a tissue-engineering chamber as an alternative islet 
transplantation site, (2) investigate the feasibility of utilis-
ing a FDA-approved Gelitaspon sponge as the islet car-
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rier and (3) to assess if the addition of 100 ng/ml NGF has 
any beneficial effects on islet graft function in strepto-
zotocin (STZ)-induced diabetic mice.
 Materials and Methods 
 Animals 
 Male C57BL/6J mice, 8–12 weeks of age, weighing 20–25 g 
were obtained from the Animal Resources Centre (Perth, W.A., 
Australia) and used as both pancreatic islet donors and islet re-
cipients. Mice were housed in an approved facility with a 12-hour 
day/night cycle with access to food and water ad libitum. All ex-
periments carried out on mice were with prior approval of the 
Animal Ethics Committee, St. Vincent’s Hospital, Melbourne, 
Vic., Australia, under the guidelines of the National Health and 
Medical Research Council (NHMRC) Australian Code of Prac-
tice for the Care and Use of Animals for Scientific Purposes and 
Principles of Laboratory Animal Care (NIH publication No. 85-
23, revised 1985; http://grants1.nih.gov/grants/olaw/references/
phspol.htm).
 Materials 
 Gelitaspon (Gelita Medical BV, Amsterdam, The Netherlands) 
is a biodegradable sponge made from purified protein obtained 
by the partial acid hydrolysis of porcine collagen. All other chem-
icals were purchased from Sigma Aldrich Pty. (Sydney, N.S.W., 
Australia) unless otherwise stated.
 Induction of Diabetes 
 Diabetes was induced in C57BL/6J mice by a single intraperi-
toneal injection of STZ (250 mg/kg body weight). STZ-induced 
diabetic mice are widely used as an animal model for diabetes, and 
have been fully characterised [Hayashi et al., 2006]. STZ is spe-
cifically taken up by   cells promoting cell death by necrosis. A 
single bolus dose induces fulminate diabetes in susceptible strains 
producing a disease that has resemblance in many aspects to non-
obese diabetic mice and human insulin-dependent diabetes mel-
litus. Diabetes in C57BL/6J mice was confirmed by non-fasting 
blood glucose (NFBG) readings taken from the tail vein using a 
glucometre (Medisense Optium Xceed; Abbott Laboratories, 
Melbourne, Vic., Australia) on 2 successive days of  6 18 mmol/l.
 Diabetic mice with BG levels  6 18 mmol/l and with a weight 
of  1 18 g were randomly assigned to the following experimental 
groups: (1) Gelitaspon + NGF + islets (n = 5), (2) Gelitaspon + is-
lets (n = 4) and (3) Gelitaspon only (n = 6).
 Islet Isolation 
 C57BL/6J mice were euthanised by cervical dislocation and 
islets isolated by bile duct cannulation and collagenase digestion 
(Collagenase P; Roche Diagnostics, Mannheim, Germany) of the 
pancreas. Islets were purified by density gradient (Histopaque-
1077; Sigma Aldrich Pty.) and resuspended in CMRL 1066 media 
(Life Technologies, Gaithersburg, Md., USA) supplemented with 
10% foetal calf serum, 200 mmol/l  L -glutamine, 100 U/ml penicil-
lin and 100   g/ml streptomycin, pH 7.4. The isolated islets were 
hand picked using a stereomicroscope (Nikon Eclipse 55i; Nikon 
Tec Corp., Tokyo, Japan), and cultured overnight in supplement-
ed CMRL media at 37 ° C in humidified 5% CO 2 /95% air.
 The Surgical Model 
 All surgery on diabetic C57BL/6J mice was performed under 
aseptic conditions using 2% isoflurane inhalational anaesthesia 
with supplemental oxygen (2 l/min) and performed using an op-
erating microscope (Carl Zeiss Inc., Jena, Germany). Implanta-
tion of the chambers was based on a modified method as de-
scribed previously [Cronin et al., 2004]. Each experimental group 
was implanted with chambers made from silicone tubing (Dow-
Corning Corp., Midland, Mich., USA) with an internal volume of 
44   l. Chambers were split along their length to enfold around 
the femoral vessels and nerve. This neurovascular bundle was 
mobilised from the underlying fascial layer by ligating side 
branches to site the chamber. Five hundred islets were seeded onto 
(1) Gelitaspon discs ( fig. 1 ) soaked with phosphate buffered saline 
(PBS), pH 7.4 (PBS) containing 100 ng/ml NGF (BD Biosciences, 
Billerica, Mass., USA) (Gelitaspon + islets + NGF group; n = 5) 
and (2) Gelitaspon discs soaked in PBS (Gelitaspon + islets group; 
n = 4). A final group of diabetic mice had a Gelitaspon disc soaked 
in PBS, but with no islets or NGF (Gelitaspon only group; n = 6).
 Gelitaspon only or Gelitaspon with islets in the absence or 
presence of NGF was transferred into the chamber ( fig. 2 ) and the 
silicone tubing was then sealed along its length with bone wax 
(Ethicon Inc., Somerville, N.J., USA). The distal end was closed 
by mobilising the inguinal fat pad and incorporating it into the 
distal end of the chamber. The proximal end was sealed with bone 
wax and the wound closed with metal clips.
 Monitoring the Diabetic Mice 
 Mice were assessed weekly for NFBG as described above 
throughout the treatment period. At 8 weeks after transplanta-
tion all mice underwent an intraperitoneal glucose tolerance test 
(IPGTT). Mice were fasted and cage bedding material removed 
(but water allowed) for 18 h prior to the test. Fasting BG levels 
were determined at commencement to provide a baseline reading. 
 D -glucose (300 mg/ml in saline) was injected intraperitoneally at 
a dose of 2 mg/g body weight. BG was measured at 15, 30, 45, 60, 
120 and 180 min. For comparison, a cohort of non-diabetic 
C57BL/6J mice (n = 6) also underwent an IPGTT.
 Harvesting the Graft Tissue 
 On completion of the IPGTT, mice were anaesthetised using 
2% isoflurane inhalational anaesthesia with supplemental oxygen 
(2 l/min). The chambers were harvested surgically by ligating the 
femoral vessels, and pancreata harvested for further histological 
analysis. After removal of the chamber and pancreata, mice were 
then euthanised with an intracardiac injection of 0.3 ml pento-
barbitone (Lethobarb; Virbac, Milperra, N.S.W., Australia).
 Histological and Immunohistochemical Analysis  
 All tissue was fixed in 4% paraformaldehyde at 4 ° C overnight 
before being processed and paraffin embedded. Serial 5-  m sec-
tions were mounted onto slides coated with 3-aminopropyl-
triethoxysilane and dried overnight at 37 ° C.
 Serial chamber graft and pancreatic sections were deparaf-
finised and rehydrated. Sections for routine histological mor-
phology were visualized by staining with Mayer’s haemotoxylin 
and eosin (HE) and with Giemsa solution for lymphocyte stain-
ing. Sections were mounted with a glass cover slip and Depex.
 Insulin was detected on every 100-  m section using a DAKO 
Autostainer (Dako Cytomation, Carpenteria, Calif., USA). Sec-
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tions were blocked for endogenous peroxidase with 3% hydrogen 
peroxide in 50% methanol, followed by antigen retrieval using 
proteinase K (Dako Cytomation). Sections were incubated in a 
polyclonal antibody directed against guinea pig insulin (1: 100 di-
lution; Dako Cytomation) for 1 h. Secondary antibody labeling 
was achieved by using rabbit immunoglobulin conjugated to per-
oxidase-labelled polymer (Rabbit Envision; Dako Cytomation) 
for 30 min and reactivity was visualized using diaminobenzalde-
hyde (DAB).
 For detection of macrophages, sections were blocked for en-
dogenous peroxidase with 3% hydrogen peroxide and blocked for 
non-specific binding before adding a monoclonal antibody di-
rected against mouse F4/80 (1: 500 dilution; Abcam Inc., Cam-
bridge, Mass., USA) diluted in 5% normal rabbit serum for 1 h. 
Secondary detection was achieved through incubation with a rab-
bit antibody directed against rat biotin (1: 200; Dako Cytomation) 
followed by HRP-streptavidin (1: 400). Reactivity was visualized 
using DAB.
 Detection of sympathetic nerves was achieved by heat-induced 
antigen retrieval by boiling in 10 m M citrate buffer, pH 6.0. Sec-
tions were blocked for endogenous peroxidase with 3% hydrogen 
peroxide and non-specific binding followed by a rabbit polyclonal 
antibody directed against rat tyrosine hydroxylase (1: 500 dilu-
tion) for 1 h. Secondary detection was achieved through incuba-
tion with a goat biotinylated antibody directed against rabbit IgG 
(1: 200 dilution; Vector Laboratories Inc., Burlingame, Calif., 
USA) followed by HRP-streptavidin (1: 400). Reactivity was visu-
alised with DAB.
 All sections were counterstained with Mayer’s haematoxylin 
and mounted with a glass cover slip and Depex.
*
g *
*
*
*
*
*
g
*
c
fv g
c
at
fv
a b
dc
 Fig. 1.  a ,  b Phase contrast images of NGF supplemented Gelita-
spon seeded with islets prior to transplantation within the cham-
ber at  ! 4 objective ( a ) and the same image at  ! 20 objective ( b ). 
 * = Islet; g = Gelitaspon. Red line encircles the position of islets 
within the Gelitaspon.  c ,  d Islet grafts during surgery and at 12 
weeks after transplantation in an STZ-induced diabetic mouse.
 c Islets seeded onto NGF-supplemented Gelitaspon in an open 
silicone chamber enclosing the femoral vessels and nerve prior to 
sealing the chamber with bone wax.  d Islet graft at 12 weeks after 
chamber transplantation in an STZ-induced diabetic mouse 
showing well-vascularised adipose tissue. Photographs were tak-
en using an operating microscope (Carl Zeiss). fv = Femoral ves-
sels; g = NGF supplemented Gelitaspon with islets; c = silicone 
chamber; at = vascularised adipose tissue. 
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 TUNEL Analysis 
 Detection of apoptosis was performed using a DeadEnd TM 
Colorimetric TUNEL System (Promega Corporation, Madison, 
Wisc., USA). Sections from chamber islet grafts were deparaf-
finised, rehydrated and antigen retrieval achieved using pro-
teinase K. Sections were equilibrated with buffer before adding 
recombinant terminal deoxynucleotidyl transferase reaction 
mix for 1 h at 37 ° C. Reaction was terminated by immersing 
slides in sodium citrate solution. Slides were washed in PBS and 
sections blocked for endogenous peroxidase. Detection of TU-
NEL-positive cells was achieved through an avidin-biotin-HRP 
detection system (ABC Elite; Vector Laboratories Inc.) and re-
activity visualized using DAB. All sections were counterstained 
with Mayer’s haematoxylin and mounted with a glass cover slip 
and Depex.
 Statistics 
 Results are reported as mean  8 SEM for the total number of 
observations, where n equals the number of mice used. Results 
were assessed by two-way mixed factorial analysis of variance 
(ANOVA) with the glucose measurements in the same animal in 
weekly BG or IPGTT treated as repeated measures and the treat-
ment groups as independent measures. A Dunnett t test was used 
post hoc where there was a single obvious control group or Stu-
dent-Newman-Keuls’ test where there was not. Values of p  ! 0.05 
were considered as statistically significant.
 Results 
 All mice in both the experimental and control groups 
survived. In the chamber groups the femoral vascular 
pedicle was found to be patent in all animals at the time 
of harvest.
 NGF Restores Glucose Levels in STZ-Induced Diabetic 
Mice 
 The minimal number of islets transplanted beneath 
the renal capsule that resulted in a return to normogly-
caemic levels in STZ-induced diabetic mice was 500 [un-
publ. data]. Diabetic mice transplanted with Gelitaspon 
only or with 500 islets on Gelitaspon into a flow through 
tissue engineering chamber, sited on the femoral vessels 
remained hyperglycaemic for the duration of the study. 
In contrast, mice that were transplanted with 500 islets 
on Gelitaspon in the presence of 100 ng/ml NGF demon-
strated a gradual decrease in BG ( fig. 2 a). Four of five 
mice showed a reduction in hyperglycaemic levels from 
 1 20 mmol/l to  ! 11.9 mmol/l by 4 weeks after transplan-
tation ( fig. 2 b) with a mean level of 12.28  8 1.65 mmol/l 
(n = 5) compared with the Gelitaspon with islets group 
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 Fig. 2.  a Weekly BG measurements from STZ-induced diabetic 
mice with chambers containing Gelitaspon only (triangle; n = 6), 
with chambers containing Gelitaspon + islets (circle; n = 4) and 
with chambers containing Gelitaspon + NGF + islets (square; n = 
5) over 8 weeks after transplantation. Diabetic mice transplanted 
with chambers containing Gelitaspon + NGF + islets show a sig-
nificant reduction in BG levels compared to diabetic mice trans-
planted with chambers containing Gelitaspon + islets and dia-
betic mice transplanted with chambers containing Gelitaspon 
only (p  ! 0.001, repeated measures two-way ANOVA) and the di-
rect comparison of Gelitaspon + islets and Gelitaspon + NGF + 
islets is also significant (p = 0.005). Data points are mean  8 SEM. 
 * p  ! 0.05 by t test;  b Weekly BG measurements for each STZ-in-
duced diabetic mice with chambers containing Gelitaspon + NGF 
+ islets over 8 weeks after transplantation (n = 5). Four of five 
diabetic mice show a return close to normoglycaemic levels. 
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which was 20.9  8 1.33 mmol/l (n = 4). By 7 weeks after 
transplantation, BG of the Gelitaspon + islet + NGF group 
had further decreased to a mean of 11.50  8 1.56 mmo/l 
(n = 5) and remained at this level for the remainder of the 
treatment period ( fig. 2 a). The difference in weekly BG 
between the two groups was statistically significant (p = 
0.005).
 STZ-Induced Diabetic Mice Transplanted with Islets 
and NGF Show a Relatively Normal Response to an 
IPGTT 
 To further evaluate the function of transplanted islets 
an IPGTT was performed on all groups of mice at 8 weeks 
after transplantation, and on age-matched non-diabetic 
controls ( fig. 3 a). Four of five mice transplanted with is-
lets on Gelitaspon in the presence of NGF demonstrated 
a response similar to non-diabetic controls, initially ris-
ing higher but returning to baseline levels at completion 
of the IPGTT ( fig. 3 b). This group of mice was signifi-
cantly different when compared to mice transplanted 
with islets on Gelitaspon or Gelitaspon only groups. Both 
of these later groups remained hyperglycaemic for the 
duration of the IPGTT, demonstrating a diminished ca-
pacity for glucose tolerance ( fig. 3 a).
 Islet Survival Is Enhanced with NGF 
 Haematoxylin and eosin staining of serial sections of 
the Gelitaspon with islets and NGF containing chamber 
grafts revealed multiple islets at 8 weeks after transplan-
tation ( fig. 4 a, c). These islets generally retained an intact 
rounded appearance or aggregates of multiple islets with 
a disrupted architecture located adjacent to the femoral 
pedicle, and surrounded by mature vascularised adipo-
cytes ( fig. 4 a). Immunohistochemical staining for insulin 
demonstrated abundant   cells within these islets ( fig. 4 b, 
e). In comparison, there were few islets detected in sec-
tions from chambers obtained from the Gelitaspon + islet 
group, and these islets appeared to show less intense 
staining for insulin, suggesting a compromised function 
( fig. 4 f). Cells within islets from both groups were nega-
tive for apoptosis ( fig. 4 g, h).
 Immunohistochemical staining for insulin produc-
tion in serial sections of pancreata harvested from the 
chamber groups was negative, demonstrating that STZ 
specifically lead to death of   cells in the pancreas. This 
supports the finding that the improved glycaemic and 
glucose tolerance was due to the islet grafts.
 Staining for F4/80 showed intense staining for macro-
phages within the fibrous capsule surrounding the grafts 
of both groups ( fig. 5 a, e). Macrophages were observed 
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 Fig. 3.  a IPGTT results for STZ-induced diabetic mice with cham-
bers containing Gelitaspon only (triangle; n = 6), with chambers 
containing Gelitaspon + islets (circle; n = 4), with chambers con-
taining Gelitaspon + NGF + islets (square; n = 5) and non-dia-
betic control mice (diamond; n = 5). The Gelitaspon + NGF + islet 
group shows an improved response compared to Gelitaspon + is-
lets (p  ! 0.05, two-way repeated measures ANOVA, post hoc SNK) 
and although the Gelitaspon + NGF + islet group had a similar 
response to that of non-diabetic controls there was still a statisti-
cally significant difference (p  ! 0.05). Data points are mean  8 
SEM;  b IPGTT results for all STZ-induced diabetic mice with 
chambers containing Gelitaspon + NGF + islets (n = 5). 
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surrounding some islets within the grafts from the Geli-
taspon + islet group, but not within grafts from the Geli-
taspon + islet + NGF group ( fig. 5 b, f). Lymphocytes were 
observed within grafts from both the islet groups in close 
proximity to blood vessels, but not surrounding islets 
( fig. 5 c, d, g, h).
 NGF Improves Nerve Reinnervation of Transplanted 
Islets 
 To evaluate reinnervation within transplanted islets, 
sections from islet grafts were stained for tyrosine hy-
droxylase (TH). Nerve fibres positive for TH were ob-
served distributed within islets treated with NGF ( fig. 6 c, 
d). Nerve fibres positive for TH were also observed with-
in untreated islets, located around the periphery of the 
islet ( fig. 6 b).
 Discussion 
 This study has shown that the biodegradable scaffold 
Gelitaspon, combined with NGF and placed into a sub-
cutaneously sited vascularised tissue-engineering cham-
ber around the femoral neurovascular pedicle provides a 
suitable vehicle for islet transplantation in a murine mod-
el of diabetes. We demonstrate that diabetic mice trans-
planted with islets seeded onto Gelitaspon with NGF 
show a significant reduction in weekly NFBG, and when 
challenged with an IPGTT show a response close to that 
of non-diabetic mice. This subcutaneous, accessible and 
protected chamber technique of islet delivery has several 
attractions. Gelitaspon is an absorbable gelatin sponge of 
porcine origin approved by the FDA, and is currently 
used clinically in surgical wounds.   -Gelatin, the major 
component, is a purified protein obtained by the partial 
acidic hydrolysis of collagen, and contains an amino acid 
composition homologous to human collagen and is read-
ily biodegradable. It has the advantage of being relatively 
cheap, easily manufactured and is suitable as a carrier for 
large quantities of cells allowing in-growth of vessels and 
diffusion of oxygen and nutrients from recipient tissues.
 Other macroporous gelatin scaffolds have been utilised 
as islet carriers successfully in vitro and in vivo. Dis-
persed bovine islets cultured in gelatin beads maintained 
their capacity for increased insulin secretion after a glu-
cose challenge [Del Guerra et al., 2001]. In a recent study, 
diabetic mice transplanted with islets, seeded into colla-
gen IV-coated macroporous gelatin scaffolds into the ep-
ididymal fat pad achieved euglycaemia that was main-
tained for up to 297 days, and showed a normal glucose 
response when challenged with an IPGTT [Salvay et al., 
2008]. Encouraging results have also been shown in clin-
ical trials with the transplantation of autologous kerati-
nocytes seeded into gelatin microbeads in the healing of 
chronic leg ulcers [Liu et al., 2004]. Our study using Geli-
taspon as the scaffold demonstrated islet survival and 
function in the short term. The effects of long-term stud-
ies on islet survival and function are still to be under-
taken.
 Fig. 5. Histological and Immunohistochemical staining for in-
flammatory cells in grafts from STZ-induced diabetic mice trans-
planted with chambers containing Gelitaspon + NGF + islet or 
Gelitaspon + islet.  a–d Grafts from the Gelitaspon + NGF + islet 
group stained for macrophages with anti-F4/80;  ! 40 objective ( a , 
 b ); lymphocytes using a Giemsa stain;  ! 40 objective ( c ,  d ). Grafts 
showed intense staining for macrophages within the fibrous cap-
sule surrounding the graft and lymphocytes were observed with-
in the graft close to vessels. Macrophages and lymphocytes were 
not observed near islets. Grafts from the Gelitaspon + islet group 
stained for macrophages with anti-F4/80;  ! 40 objective ( e ,  f ); 
lymphocytes using a Giemsa stain;  ! 40 objective ( g ,  h ). Grafts 
showed intense staining for macrophages within the fibrous cap-
sule surrounding the grafts and surrounding some islets within 
the grafts and lymphocytes were observed within the graft close 
to vessels. Lymphocytes were not observed near islets. Arrows 
show macrophages.  * = Islets; l = lymphocytes; v = vessel. Bars in 
micrographs represent 50   m. Micrographs are representative of 
3 serial sections. 
(For figure see next page.)
 Fig. 4. Histological and immunohistochemical staining for HE, 
insulin and TUNEL in grafts from STZ-induced diabetic mice 
transplanted with chambers containing Gelitaspon + NGF + is-
lets or Gelitaspon + islets. Grafts from the Gelitaspon + NGF + 
islets group stained for HE ( a ) and insulin ( b ). Islets are located 
close to the femoral pedicle and stain intensely for insulin;  ! 10 
objective; bar in micrographs represents 100   m. Graft from the 
Gelitaspon + NGF + islet group stained for HE ( c ), insulin ( e ) and 
TUNEL ( g ). Islet shows intense staining for insulin and is nega-
tive for TUNEL;  ! 40 objective. Graft from the Gelitaspon + islet 
group stained for HE ( d ), insulin ( f ) and TUNEL ( h ). Islet shows 
a reduced staining for insulin and is negative for TUNEL;  ! 40 
objectives. at = Adipose tissue;  * = islets; fp = femoral pedicle;
fn = femoral nerve; a = artery; v = vein. Bars in micrographs rep-
resents 50   m. Micrographs are representative of 3 separate se-
rial sections. 
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 Subcutaneous sites are attractive for islet transplanta-
tion as they require less invasive procedures. Successful 
subcutaneous islet transplantation has, however, been 
difficult to achieve requiring either a period of pre-vas-
cularisation before transplantation [Pileggi et al., 2006], 
or islet encapsulation strategies [Kawakami et al., 2000] 
to treat diabetic rodents. For example, in a recent study 
by Pileggi et al. [2006], a biocompatible, cylindrical stain-
less steel mesh device was used to create a well-vascular-
ised environment prior to islet transplantation in diabet-
ic rats. The diabetic rats demonstrated a return to normo-
glycaemic levels that was maintained for more than 160 
days. Islet transplantation under the kidney capsule 
[Morini et al., 2007], epididymal fat pad [Chen et al., 
2007] and spleen [Gustavson et al., 2005] have been suc-
cessful in reversing diabetes in rodents. However, these 
sites are not ideal in the clinical setting. Vascularisation 
is the key to islet survival and the design of the chamber 
used in this study focuses on this. The islet seeded NGF 
and Gelitaspon discs are brought into close proximity 
immediately adjacent to a rapidly expanding rich blood 
supply so that a pre-vascularisation period is not required. 
This is supported by a recent clinical study by Prochorov 
et al. [2008], in which transplantation of encapsulated 
rabbit islets ( 1 6,000 IEQs) into a vascular lumen reduced 
insulin dependence in 73.7% of the patients within 2 
years.
 NGF is one of many intrinsic factors that support pan-
creatic islet function and survival. As well as having neu-
rotrophic actions, NGF plays an important regulatory 
role in   cell function. NGF has been shown to modulate 
  cell plasticity by promoting neurite-like outgrowth in 
fn it
it
it
a b
c d
20 µm
20 µm
20 µm
20 µm
 Fig. 6. Immunohistochemical staining for nerves using an anti-
body directed against TH in grafts from STZ-induced diabetic 
mice transplanted with Gelitaspon + islets in the presence or ab-
sence of NGF;  a femoral nerve showing fibers positive for TH (ar-
rows);  b graft from the Gelitaspon + islet group showing 5 nerves 
around the periphery of the islet tissue (arrows);  c ,  d grafts from 
the Gelitaspon + islet + NGF group showing nerves in the islet 
tissue (arrows). 
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primary cultures of foetal and adult   cells [Vidaltamayo 
et al., 1996] and in insulinoma cell lines [Polak et al., 
1993], and has been shown to enhance glucose-stimulat-
ed insulin secretion from the INS-1 insulinoma cell line 
[Frodin et al., 1995]. Cultured human   cells express NGF 
as well as the NGF receptors gp140 Trk-A and p75 NTR 
[Pierucci et al., 2001]. Blockage of these receptors in   
cells with an anti-NGF antibody or NGF withdrawal in-
duces apoptosis in vitro. In recent studies, islets cultured 
with up to 500 ng/ml NGF showed improved viability, by 
inhibiting apoptosis, and improved insulin secretory 
function. NGF-treated islets transplanted beneath the re-
nal capsule of diabetic mice showed a significantly im-
proved glucose tolerance compared to non-NGF-treated 
islets [Miao et al., 2005, 2006]. Furthermore, local NGF 
treatment of islets was more effective at reversing diabe-
tes in mice than by systemic application [Miao et al. 
2006].
 NGF has also been shown to induce a potent angio-
genic response in vitro [Cantarella et al., 2002] and pro-
mote angiogenesis and arteriogenesis in ischaemic hind 
limbs accelerating tissue recovery, when delivered daily 
over 14 days after ischaemia [Emanueli et al., 2002]. We 
quantified percent vascular volume within islets in our 
study (data not shown), and found no statistically signif-
icant differences at 12 weeks after transplantation be-
tween grafts in the presence or absence of NGF.
 NGF, delivered by controlled release, has been shown 
to enhance sciatic nerve regeneration [Lee et al., 2003]. 
The observed beneficial effect of NGF on islet function in 
our chamber model could be due to an NGF-induced in-
crease in autonomic nerve growth into the transplanted 
islets. Sections from our chamber grafts stained for the 
sympathetic marker TH did show some difference in ex-
pression within islets through the addition of NGF. How-
ever, these results remain inconclusive as better islet sur-
vival may itself have led to better innervation. Further 
histological investigations including staining for vesicu-
lar monoamine transporter will possibly allow for a more 
quantitative assay of sympathetic islet innervation.
 In our study, diabetic mice transplanted with islets 
seeded onto Gelitaspon in the presence of NGF showed a 
significant reduction in NFBG and a response to an
IPGTT close to that seen in non-diabetic controls, com-
pared with islets in the absence of NGF, but did   observe 
intense staining for insulin and difference in TH staining 
of nerves within islets treated with NGF compared with 
non-treated islets. Given our mode of NGF delivery, one 
bolus dose at time of transplantation with Gelitaspon and 
islets, we conclude that in our study NGF may have im-
proved islet viability and secretory function in our tissue-
engineering chamber model. This chamber model has 
the advantage that if previous islet transplantation at-
tempts have resulted in poor islet engraftment, there is an 
opportunity to transplant more islets by accessing the ex-
isting wound. Alternatively, if there are any adverse reac-
tions experienced as a result of this method, the chamber 
can be easily removed. In conclusion, we have demon-
strated in this study that islets are efficiently transplanted 
in vascularised chambers based on the neurovascular 
femoral artery, vein and nerve, in the presence of a gelatin 
sponge scaffold with NGF. Syngeneic islets transplanted 
with this method were capable of successfully maintain-
ing glycaemic control in STZ-induced diabetic mice in 
short-term studies. For future investigation, we intend to 
conduct long-term studies using Gelitaspon and NGF, 
and to examine how allogeneic islets can also be immune 
protected using this model of islet transplantation.
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